2Ezzat S, Sarti DA, Cain DR, et al. Thyroid incidentalomas. Prevalence by palpation and uhrasonography [J]. Arch Intern Med, 1994,154( 16): 1838-1840.
3McCoy KL, Jabboar N, Ogilvie JB, et al. The incidence of cancer and rate of false-negative cytology, in thyroid nodules greater than or equal to 4 cm in size[J]. Surgery, 2007,142(6):837-844.
4Gharih H, Papini E, Pasehke R, et al. American association of clinical endocrinologists, associazione medici endocrinologi, and European thyroid association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations[J]. Endocr Pratt, 2010, 16(3):468-475.
5Baloch Z, Carayon P, Conte-Devolx B, et al. Guidelines Committee, National Academy of Clinical Biochemistry. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease [J]. Thyroid, 2003,13(1): 3-126.
6Boelaert K, Horacek J, Holder RL, et al. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fi ne-needle aspiration [J].J Clin Endo Metab, 2006,91 ( I 1 ):4295-4301.
7Wong CK, MH W. Thyroid nodules: rational management [J]. World J Surg, 2000, 24(8):934-941.
8American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11): 1167-1214.
9Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin en the diagnosis and cutcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disnrde [J]. Clin Endocrinol Metab, 2004,89(1): 163-168.
10Moon WJ, Jung SL, Lee JH, et al. Benign and Malignant Thyroid Nodules: US Differentiation-Multicenter Retrospective Study [J ]. Radiology, 2008, 247(3):762-770.
